Drug & Device Development
NEW YORK (Reuters Health) - Monotherapy with the investigational GLP-1 receptor antagonist lixisenatide significantly reduces postprandial glucose excursions and HbA1c in treatment-naïve type 2 diabetics, according to a new report.
"No other placebo-controlled studies are available for GLP-1 receptor agonist monotherapy in a similar patient population," note Dr. Vivian A. Fonseca, with Tulane University Health Sciences Center in New Orleans, Louisiana, and colleagues in diabetes
Care online March 19.
They point out that while two other GLP-1 receptor agonists are currently on the market -- exenatide (Byetta, Bydureon) and liraglutide (Victoza) -- lixisenatide is highly selective for the GLP-1 receptor, and stimulation of insulin secretion with lixisenatide depends "strictly" on glucose levels.
In the current randomized double-blind, 12-week study, 361 drug-naive patients with type 2 diabetes
and HbA1c levels between 7% and 10% were assigned to once-daily subcutaneous lixisenatide regimens that increased in dosage in two steps (10 mcg for1 week, 15 mcg for 1 week, and then 20 mcg) or in one step (10 mcg for 2 weeks and then 20 mg) or to similar placebo regimens.
The proportion of patients achieving an HbA1c ril
www red DiabetologNytt